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Abstract
Background: Point-of-care testing (POCT) of coagulation has been proven to be of great value in accelerating
emergency treatment. Specific POCT for direct oral anticoagulants (DOAC) is not available, but the effects of DOAC
on established POCT have been described. We aimed to determine the diagnostic accuracy of Hemochron®
Signature coagulation POCT to qualitatively rule out relevant concentrations of apixaban, rivaroxaban, and
dabigatran in real-life patients.
Methods: We enrolled 68 patients receiving apixaban, rivaroxaban, or dabigatran and obtained blood samples at
six pre-specified time points. Coagulation testing was performed using prothrombin time/international normalized
ratio (PT/INR), activated partial thromboplastin time (aPTT), and activated clotting time (ACT+ and ACT-low range)
POCT cards. For comparison, laboratory-based assays of diluted thrombin time (Hemoclot) and anti-Xa activity were
conducted. DOAC concentrations were determined by liquid chromatography-tandem mass spectrometry.
Results: Four hundred and three samples were collected. POCT results of PT/INR and ACT+ correlated with both
rivaroxaban and dabigatran concentrations. Insufficient correlation was found for apixaban. Rivaroxaban
concentrations at <30 and <100 ng/mL were detected with >95% specificity at PT/INR POCT ≤1.0 and ≤1.1 and
ACT+ POCT ≤120 and ≤130 s. Dabigatran concentrations at <30 and <50 ng/mL were detected with >95%
specificity at PT/INR POCT ≤1.1 and ≤1.2 and ACT+ POCT ≤100 s.
Conclusions: Hemochron® Signature POCT can be a fast and reliable alternative for guiding emergency treatment
during rivaroxaban and dabigatran therapy. It allows the rapid identification of a relevant fraction of patients that can
be treated immediately without the need to await the results of much slower laboratory-based coagulation tests.
Trial registration: Unique identifier, NCT02371070. Retrospectively registered on 18 February 2015.
Keywords: Point-of-care testing, POCT, Direct oral anticoagulants, DOAC, Non-vitamin K antagonist oral anticoagulants,
NOAC, Emergency surgery, Anticoagulation reversal, Thrombolysis, Stroke
Background
Direct oral anticoagulants (DOAC) are being increasingly
prescribed. Consequentially, more DOAC-treated patients
are admitted to emergency units across all clinical special-
ties. Importantly, emergency coagulation testing in DOAC-
treated patients has not been solved, which complicates
emergency treatment decisions such as emergency surgery,
anticoagulation reversal, and thrombolysis in ischaemic
stroke.
In patients receiving vitamin K antagonists (VKA),
point-of-care testing (POCT) of coagulation has proven
its great value in accelerating emergency treatment [1].
Although DOAC-specific POCT is not currently available,
results obtained by our group suggest that relevant plasma
concentrations of rivaroxaban can be qualitatively ruled
out with CoaguChek® (Roche, Basel, Switzerland), a pro-
thrombin time/international normalized ratio (PT/INR)
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POCT designed for VKA monitoring [2]. However,
CoaguChek® lacked sensitivity to apixaban and dabigatran.
Hemochron® Signature (ITC, Edison, NJ, USA) is
another coagulation POCT that uses a different PT/INR
assay to CoaguChek® and has additional measuring cap-
ability for activated partial thromboplastin time (aPTT)
and activated clotting time (ACT). Previous reports indi-
cate that Hemochron® Signature is responsive to rivaroxa-
ban and dabigatran [3–7]. However, these reports aimed
at quantitative measurements rather than qualitatively rul-
ing out low but relevant DOAC concentrations, and used
either artificially DOAC-spiked plasma samples [3, 4] or
they only comprised a few samples with low DOAC con-
centrations [5–7]. Furthermore, the utility of Hemochron®
Signature to measure the effects of apixaban on coagula-
tion effects has never been reported. Thus, the diagnostic
value of Hemochron® Signature in guiding emergency
treatment decisions in DOAC-treated patients has not
been clarified.
Methods
Study aim and design
We aimed to determine the diagnostic accuracy of
Hemochron® Signature to qualitatively rule out relevant
concentrations of apixaban, rivaroxaban, and dabigatran
in real-life patients.
The study was a single-centre, prospective observational
trial with blinded end-point assessment. The Clinical
Trial Registration Information unique identifier is
NCT02371070.
Setting and eligibility criteria
The study was conducted at the Department of
Neurology & Stroke and the Department of Cardiology
and Cardiovascular Medicine of Tübingen University
Hospital, Tübingen, Germany, a tertiary care facility.
Patients receiving first doses of apixaban, rivaroxaban, or
dabigatran were enrolled. Exclusion criteria were known
coagulopathy, abnormal coagulation at baseline (PT >13 s/
Quick <70%/INR >1.2 or aPTT >37 s), intake of VKA or
DOAC within 14 days, low-molecular-weight heparins
within 24 h or unfractionated heparin within 12 h prior to
DOAC intake. Use of antiplatelet agents was permitted.
Predominantly low dabigatran concentrations in these
samples required inclusion of additional samples from
patients on maintenance therapy with dabigatran. The
same exclusion criteria as above applied, except that
abnormal coagulation at baseline (due to dabigatran
intake) was allowed.
Sample collection
Six blood samples were collected from each subject via
an indwelling venous catheter or venipuncture: before
DOAC intake, 30 min and 1, 2, and 8 h after intake, and
at trough (12 h for apixaban and dabigatran, 24 h for
rivaroxaban).
POCT and laboratory-based coagulation testing
Bedside POCT of PT/INR, aPTT and ACT was conducted
from whole blood. ACT was measured using ACT plus
(ACT+) and ACT-low range (ACT-LR) test cards that
contain different reagents and cover different measure-
ment ranges. Further samples were collected in 3.2%
sodium-citrate tubes (Sarstedt, Nümbrecht, Germany),
and instantly centrifuged to acquire plasma. Laboratory-
based anti-Xa activity was measured using Chromogenix
COAMATIC Heparin Test on an ACL TOP 700 (Instru-
mentation Laboratory, Kirchheim, Germany). TECHNO-
VIEW calibrators (Technoclone, Vienna, Austria) were
used to determine apixaban and rivaroxaban concentra-
tions with limits of quantification of 10 and 18 ng/mL.
Remaining plasma aliquots were stored at –80 °C until
testing of diluted thrombin time (dTT; Hemoclot assay,
Hyphen BioMed, Neuville-sur-Oise, France). As the gold
standard, DOAC concentrations were determined by
ultra-performance liquid chromatography-tandem mass
spectrometry (UPLC-MS) [8]. All coagulation testing was
performed according to manufacturers’ instructions by
thoroughly trained investigators and technicians.
Blinding
All laboratory-based tests, including UPLC-MS, were
conducted and interpreted by technicians blinded to
POCT results.
Definition of relevant DOAC concentrations
Our analyses were based on two likely emergency scenarios
(Table 1). First, we investigated if POCT can be used to
detect DOAC concentrations proposed as safe for surgical
procedures [9–12]. As two of the proposed safe-for-
treatment thresholds for dabigatran are practically identical
(<48 ng/mL and <50 ng/mL), we chose to evaluate
the <50 ng/mL threshold only. For apixaban a concentra-
tion threshold that permits surgery is currently unknown
[13]. Second, we evaluated concentrations that may allow
thrombolysis in ischaemic stroke according to an expert
recommendation [14].








as safe for surgery [10–12]
30 NA 30, 48, 50
DOAC concentrations that may
permit thrombolysis with rtPA [14]
100 10 50
DOAC direct oral anticoagulants, NA not available, rtPA recombinant tissue
plasminogen activator
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Statistics
For test performance analyses, results of samples (all
baseline samples, all samples per DOAC) were pooled in
order to obtain a clinically relevant concentration
spectrum. SPSS v23 (IBM, Armonk, NY, USA) was used
for statistics. Confidence intervals for proportions, i.e.
diagnostic sensitivity and specificity, were calculated
according to the efficient-score method using the free
online VassarStats Clinical Calculator 1 [15]. Pearson’s
correlation coefficient was used to estimate the strength
of correlations between coagulation assays and DOAC
concentrations. Correlation strength was graded as
proposed by Evans: <0.20 very weak, 0.20–0.39 weak,
0.40–0.59 moderate, 0.60–0.79 strong, and >0.80 very
strong [16]. Fisher’s exact test was calculated to deter-
mine differences in the proportions of baseline POCT
results between the study groups and to examine the
association between coagulation test results and DOAC
concentrations dichotomized to concentrations below
and above the chosen safe-for-treatment thresholds
(Table 1). Diagnostic accuracy of coagulation tests at
different cut-off points was expressed in terms of
sensitivity, specificity, positive predictive value (PPV),
negative predictive value (NPV), and likelihood ratio.
Sensitivity was defined as the percentage of samples with
DOAC concentrations below the chosen safe-for-
treatment threshold that were correctly identified as
eligible for treatment. Correspondingly, specificity was
defined as the percentage of samples with DOAC con-
centrations above the corresponding threshold that were
correctly identified as not eligible. Specificity >95% was
defined as sufficient for clinical application. PPV was
defined as the percentage of samples with DOAC con-
centrations below the chosen safe-for-treatment thresh-
old of all samples identified as eligible for treatment.
NPV was defined as the percentage of samples with
DOAC concentrations above the chosen safe-for-
treatment threshold of all samples identified as not eligible
for treatment. All DOAC concentrations are reported as
median and interquartile range (IQR). Sensitivity and spe-
cificity are given with two-sided 95% confidence intervals.
Results
We enrolled 60 patients (n = 20 per DOAC) receiving first
doses of DOAC and eight patients on dabigatran mainten-
ance therapy between February 2014 and November 2015.
Patient characteristics and baseline laboratory values are
provided as part of Additional file 1: Tables S1 and S2).
Samples and DOAC concentrations
Of 408 planned samples, 403 were collected (apixaban
n = 117, rivaroxaban n = 118, dabigatran n = 168). Five
samples could not be analysed due to POCT
malfunction.
DOAC were not detected by UPLC-MS in any baseline
sample acquired before first DOAC intake (n = 60).
Samples collected after DOAC intake contained a
median concentration of 57.2 ng/mL apixaban (IQR
35.3–101.2, n = 97), 99.3 ng/mL rivaroxaban (IQR 25.7–
184.3, n = 98), and 29.0 ng/mL dabigatran (IQR 10.7–
72.3, n = 148). Median trough dabigatran concentrations
were significantly lower after the first dose than during
maintenance therapy (16.3 versus 81.8 ng/mL, p < 0.001).
Correlation between POCT results and DOAC concentrations
POCT of baseline samples before first DOAC intake
showed no difference between DOAC groups. Correla-
tions between POCT results and apixaban concentrations
were weak for PT/INR (r = 0.37, p < 0.001) and moderate
for ACT+ (r = 0.48, p < 0.001). No correlation was found
for aPTT (p = 0.857) or ACT-LR (p = 0.174). For rivar-
oxaban, correlation was strong for PT/INR and ACT+
(r = 0.79 and 0.78, both p < 0.001) and weak for aPTT
and ACT-LR (r = 0.399 and 0.383, both p <0.001).
Dabigatran concentrations correlated strongly with all
test cards (PT/INR, r = 0.75; aPTT, r = 0.75; ACT-LR,
r = 0.69; ACT+, r = 0.67; all p < 0.001). Figure 1 shows
the relations of the four POCT test cards to DOAC
concentrations.
Due to insufficient correlation strength for apixaban, we
limited all further analyses to rivaroxaban and dabigatran.
To maximize clinical applicability, we focused on the two
test cards that provided strong correlation to both rivarox-
aban and dabigatran, i.e. PT/INR and ACT+.
Diagnostic accuracy of POCT
Rivaroxaban concentration was <30 ng/mL in 46/118
and <100 ng/mL in 79/118 samples. Dabigatran concen-
tration was <30 ng/mL in 95/168 and <50 ng/mL in
117/168 samples. PT/INR and ACT+ POCT results for
samples below and above each of the investigated safe-for-
treatment thresholds differed significantly (all p < 0.001;
Fig. 2). For reasons of clarity and comparison, test accur-
acy calculations are presented in Tables 2 and 3; additional
calculations for aPTT and ACT-LR POCT cards are pre-
sented as part of Additional file 1: Table S3).
Rivaroxaban concentrations at <30 and <100 ng/mL
were detected with >95% specificity at PT/INR POCT ≤1.0
and ≤1.1 and ACT+ POCT ≤120 and ≤130 s. Dabigatran
concentrations at <30 and <50 ng/mL were detected
with >95% specificity at PT/INR POCT ≤1.1 and ≤1.2
and ACT+ POCT ≤100 s (for both thresholds). Likelihood
ratio (LR) was highest for rivaroxaban and ACT+ POCT
(<30 ng/mL, LR 15.7; <100 ng/mL, LR 16.2), and dabiga-
tran and PT POCT (<30 ng/mL, LR 34.6; <50 ng/mL, LR
33.5).
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Performance of laboratory-based DOAC-specific coagulation
assays
The calibrated anti-Xa assay (Chromogenix COA-
MATIC Heparin Test) showed the highest correlation
to rivaroxaban levels of all evaluated coagulation tests
(r = 0.94, p < 0.001). Test results predicted rivaroxaban
concentrations <30 and <100 ng/mL with a respective
specificity of 99% and 92%, and a sensitivity of 98%
and 97%.
Correlation between dTT (Hemoclot) and dabigatran
concentrations was also very strong (r = 0.86, p < 0.001).
Test results predicted dabigatran concentrations <30
and <50 ng/mL with a respective specificity of 95% and
84%, and a sensitivity of 77% and 82%.
Discussion
Summary
Results of Hemochron® Signature coagulation POCT
correlate with rivaroxaban and dabigatran, but not with
apixaban concentrations. PT/INR and ACT+ test cards
are of particular interest, as they are influenced by both
rivaroxaban and dabigatran. POCT-specific cut-offs can
be used to exclude relevant rivaroxaban and dabigatran
concentrations (Table 1) at the bedside with high
specificity.
Concentration thresholds
Data on what constitutes a relevant DOAC concentration,
i.e. a concentration that leads to clinically significant
Fig. 1 Hemochron® Signature POCT results (lines 1 to 4) plotted against concentrations of a apixaban, b rivaroxaban, and c dabigatran. Line 1:
prothrombin time/international normalized ratio (PT/INR) POCT; line 2: activated partial thromboplastin time (aPTT) POCT; line 3: activated clotting
time-low range (ACT-LR) POCT; line 4: ACT+ POCT. n = 118 samples for rivaroxaban, n = 117 samples for apixaban, and n = 168 samples
for dabigatran
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coagulation impairment, are scarce. Current guidelines
are predominantly time-based. Urgent surgical proce-
dures may be performed at trough [9, 17], i.e. 12 or
24 h after last intake of apixaban/dabigatran [18, 19]
or rivaroxaban [20], respectively. Thrombolysis for
ischaemic stroke can be performed >48 h after the
last intake of any DOAC [21]. However, significant
DOAC concentrations have been observed in patients
even beyond 48 h after the last intake [22]. Hence,
the usefulness of time-based guidelines is limited.
Furthermore, obtaining information on last DOAC
intake might be impossible in patients with stroke
and aphasia or dementia.
Specific concentration thresholds that increase bleeding
risk can currently only be estimated based on retrospect-
ive analyses [10], pharmacodynamic considerations [11],
and expert opinions [12, 14]. For surgical procedures,
concentrations of rivaroxaban <30 ng/mL [10], and
dabigatran <30 [10], <48 [11], and <50 ng/mL [12]
have been proposed as safe. For apixaban, such con-
centration thresholds are currently unknown [13]. For
acute ischaemic stroke, DOAC concentrations that
may permit thrombolysis have been suggested by an
expert group (see Table 1) [14]. It should be noted
that these latter concentrations represent an expert
opinion rather than quantitatively determined values.
a
b
Fig. 2 a Distribution of rivaroxaban concentrations found at different Hemochron® Signature POCT results of prothrombin time/international
normalized ratio (PT/INR) and activated clotting time plus (ACT+) test cards and at different anti-Xa activities (n = 118 samples). b Distribution of
dabigatran concentrations found at different Hemochron® Signature POCT results of PT/INR and ACT+ test cards, and at different Hemoclot assay
results (n = 168 samples)
Table 2 Diagnostic accuracy of Hemochron® Signature POCT for rivaroxaban
Coagulation test result Threshold (ng/mL) Specificity (%) Sensitivity (%) LR PPV (%) NPV (%)
POCT PT ≤1.0 <30 97 (89–100) 33 (20–48) 11.6 88 69
POCT PT ≤1.1 <100 96 (85–99) 38 (27–50) 9.0 93 52
POCT ACT+ ≤120 s <30 96 (87–99) 67 (52–80) 15.7 91 82
POCT ACT+ ≤130 s <100 96 (85–99) 68 (55–78) 16.2 96 68
n = 118 samples
Sensitivity and specificity are provided with 95% confidence intervals
ACT+ activated clotting time plus, LR likelihood ratio, NPV negative predictive value, POCT point of care test, PPV positive predictive value, PT prothrombin time
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Following these recommendations, we based our ana-
lysis on the concentrations proposed as safe for surgery
[9–12] and the concentrations that may permit thromb-
olysis in ischaemic stroke [14].
Coagulation testing for rivaroxaban and dabigatran
Quantification of DOAC concentrations using DOAC-
specific assays is the recommended clinical standard for
coagulation testing during DOAC treatment, i.e. anti-Xa
activity for rivaroxaban and dTT or ecarin-based assays
for dabigatran [17, 23]. Our study confirms that these as-
says provide high diagnostic accuracy for all tested DOAC.
However, we found that Hemoclot had limited specificity
and sensitivity for dabigatran concentrations <50 ng/mL, a
threshold considered safe for surgery [11, 12] and thromb-
olysis [14]. At such low dabigatran concentrations, the
reduced accuracy of Hemoclot has also been reported by
others [24].
In many institutions, availability of DOAC-specific co-
agulation assays is limited [25]. For this reason, several
authors have argued that unspecific global coagulation
assays might suffice to rule out relevant DOAC concen-
trations [14, 26, 27].
Prompt availability and instantaneous results makes
coagulation POCT an attractive option in emergency
situations. We have previously shown that relevant
concentrations of rivaroxaban can be qualitatively ruled
out with CoaguChek®, a POCT designed for VKA moni-
toring [2]. The results of our current trial suggest Hemo-
chron® Signature as a more versatile alternative: while
CoaguChek® was only responsive to rivaroxaban, results
of Hemochron® Signature PT/INR and ACT+ test cards
were altered by both rivaroxaban and dabigatran.
Interestingly, the two factor Xa inhibitors, rivaroxaban
and apixaban, differed in their effects on Hemochron®
Signature POCT results. While POCT results at differ-
ent apixaban concentrations were almost randomly
distributed (Fig. 1), a strong correlation was found for
rivaroxaban. Similar findings have been previously
reported by our group and others for POCT and
laboratory-based assays [2, 28]. To our knowledge, no
convincing explanation for this difference has yet been
provided.
Irregularities of Hemochron® Signature POCT results
in the presence of dabigatran were noted early [4].
Recently, three trials evaluated this POCT (or the
equivalent GEM® PCL Plus) for coagulation monitoring
in patients treated with rivaroxaban [6], dabigatran [5],
or both [7]. These studies reported that, in the case of
low DOAC concentrations, coagulation test results fre-
quently fell into a “normal range” previously established
in untreated volunteers and concluded that the device
cannot sufficiently distinguish between patients at
trough concentrations and untreated patients [5–7]. We
contest the usefulness of a “normal range” found in
untreated volunteers for the monitoring of DOAC. In
agreement with the previous reports, we observed that
the alterations in coagulation results in the presence of
DOAC often did not exceed values found in untreated
patients. Nevertheless, our analyses show that POCT
results below DOAC-specific cut-offs are highly predict-
ive when used to qualitatively rule out relevant concen-
trations of rivaroxaban and dabigatran.
Translation into the real world
According to the results of this study, Hemochron®
Signature can be used to qualitatively rule out relevant
concentrations of rivaroxaban and dabigatran during
DOAC therapy, and accurately identify patients who are
safe for surgery or thrombolysis. To ensure patient safety,
we chose to establish cut-off values that provide >95%
specificity. Although this limits the sensitivity of our
results (i.e. not all eligible patients are identified), our
approach allows the rapid identification of a relevant
fraction of patients that can be treated immediately
without the need to await the results of much slower
laboratory-based tests (Figs. 3 and 4). For example, out of
the 118 rivaroxaban samples included in this study, a
Hemochron® Signature ACT+ test result ≤1.2 identified 34
samples as eligible for treatment based on a rivaroxaban
threshold <30 ng/ml (Fig. 4). Out of these 34 samples, 31
were identified correctly (true positives, PPV 91%),
demonstrating the high diagnostic accuracy. However, the
limited sensitivity of our approach resulted in 15 samples
that were not identified as eligible despite containing
<30 ng/ml rivaroxaban (false negatives, NPV 82%).
Table 3 Diagnostic accuracy of Hemochron® Signature POCT for dabigatran
Coagulation test result Threshold (ng/mL) Specificity (%) Sensitivity (%) LR PPV (%) NPV (%)
POCT PT ≤1.1 <30 99 (92–100) 47 (37–58) 34.6 98 59
POCT PT ≤1.2 <50 98 (88–100) 66 (56–74) 33.5 99 56
POCT ACT+ ≤100 s <30 96 (87–99) 36 (26–47) 8.7 92 54
POCT ACT+ ≤100 s <50 98 (88–100) 31 (23–40) 15.7 97 61
n = 168 samples
Sensitivity and specificity are provided with 95% confidence intervals
ACT+ activated clotting time plus, LR likelihood ratio, NPV negative predictive value, POCT point of care test, PPV positive predictive value, PT prothrombin time
Ebner et al. Critical Care  (2017) 21:32 Page 6 of 9
Fig. 3 Proposed algorithm for emergency coagulation assessment in rivaroxaban- and dabigatran-treated patients. DOAC direct oral anticoagulant,
POCT point-of-care test
Fig. 4 Scatter plot of rivaroxaban concentrations (green area: <30 ng/mL) and activated clotting time (ACT+) POCT illustrating the diagnostic
accuracy of POCT results. Green diamonds represent samples below the safe-for-treatment threshold that are correctly identified as eligible for
immediate treatment (true positive). Blue crosses represent samples that are not detected although containing concentrations below the
safe-for-treatment threshold (false negative). These can potentially still receive delayed treatment if slower laboratory-based DOAC-specific
tests are available. Green crosses represent samples above the POCT cut-off correctly identified as not eligible for treatment (true negative).
Red diamonds represent the few samples incorrectly identified as eligible for treatment despite concentrations above the safe-for-
treatment threshold (false positive)
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Although both rivaroxaban and dabigatran can be
detected with PT/INR or ACT+ POCT, our likelihood
ratio calculations support the use of ACT+ test cards for
rivaroxaban and PT/INR test cards for dabigatran.
Importantly, since there is no single POCT cut-off
value that can safely rule out all DOAC, knowledge of the
patient’s medication history is necessary. Furthermore, the
blood concentration of all DOAC increase rapidly after
intake. Therefore, coagulation results obtained within the
first 4 h after intake are not reliable.
Strengths and limitations
Our study adds considerable insight to previous reports.
We are the first to evaluate the diagnostic accuracy of
Hemochron® Signature to qualitatively rule out relevant
DOAC concentrations of apixaban, rivaroxaban, and
dabigatran. To the best of our knowledge, apixaban has
never been tested with this device before. In a departure
from previous studies, we aimed at establishing DOAC-
specific cut-offs to provide clinicians with a practical
tool for decision making during emergency treatment.
All samples were acquired from real-life patients, avoiding
the use of spiked plasma. Primarily collecting samples dur-
ing treatment initiation rather than a steady state provided
a high number of samples containing very low DOAC
concentrations. Compared to previous studies [5–7], this
allowed superior assessment of how such low concentra-
tions influence coagulation assays. Due to low dabigatran
concentrations in samples collected during treatment ini-
tiation, we decided to include samples from eight patients
on maintenance therapy. Although this adds heterogeneity
to our patient population, we did not find differences in
correlation to POCT results between the two groups. Six
sequential samples were acquired from each patient.
Hence, a bias due to repeated measurements in individual
patients cannot be excluded but this approach allowed us
to cover a wide spectrum of DOAC concentrations. Due
to the use of venous blood in this study, our results cannot
be extended to test results obtained from capillary sam-
ples. However, as venous access is routinely obtained in all
emergency patients we do not expect this to limit the
clinical applicability of our results.
What constitutes a clinically relevant DOAC concen-
tration is a matter for debate, and the concentration
thresholds investigated in our study, albeit based on
current literature, have not been confirmed by prospective
clinical trials. Furthermore, generalizability of our results
is limited by the single-centre nature of our trial. For these
reasons, validation of our data is warranted, ideally includ-
ing clinical outcome-oriented end-points.
Conclusions
Our results suggest that Hemochron® Signature POCT
in combination with PT/INR or ACT+ test cards can be
used to qualitatively rule out relevant concentrations of
rivaroxaban and dabigatran, but not of apixaban.
Thus, Hemochron® Signature POCT can be a fast and
reliable alternative for guiding emergency treatment
during rivaroxaban and dabigatran therapy. It allows the
rapid identification of a relevant fraction of patients that
can be treated immediately without the need to await
the results of much slower laboratory-based coagulation
tests. The high clinical relevance of this question
warrants a large-scale trial to investigate the clinical
safety of this approach.
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